Glycyrrhizic Acid Alleviates Osimertinib-Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation

This study investigates the potential of glycyrrhizic acid (GA), a key component of licorice, to alleviate cutaneous toxicity caused by Osimertinib, a treatment for EGFR-mutated non-small cell lung cancer. Osimertinib often leads to skin issues such as rash, itching, and hair loss. In experiments with mice, GA at a dose of 30 mg/kg/day was found to reduce the severity and frequency of these skin toxicities, restore epidermal thickness, decrease DNA damage, and lower inflammatory markers like CCL2, CCL27, and IL18. These findings suggest that GA could serve as a beneficial adjunct therapy to mitigate the adverse skin effects associated with Osimertinib treatment.